Results 201 to 210 of about 65,623 (263)

Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+‐year results from a multicenter, open‐label study

Arthritis &Rheumatology, Accepted Article.
Objective To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients 2–17 years with active pcJIA and inadequate response ...
Hermine I Brunner, Lyudmila Grebenkina, Irina Nikishina, Ekaterina Alexeeva, Vyacheslav Chasnyk, Carlos Abud‐Mendoza, Nadina Rubio‐Pérez, Heinrike Schmeling, María del Rocio Maldonado‐Velázquez, Diane Brown, Andrew Zeft, Esi Morgan, C. Egla Rabinovich, Daniel Kingsbury, Hulya Bukulmez, Beth Gottlieb, Thomas Griffin, Lisa Imundo, Stacey Tarvin, Earl Silverman, Laura Shaughnessy, Saori Shimizu, Paulette Williams, Rocío Lledó‐García, Gauri Utturkar, Baran Ufuktepe, Alberto Martini, Daniel Lovell, Nicolino Ruperto   +28 more
wiley   +1 more source

Context, Mechanisms and Outcomes of Reasonable Adjustments Across Acute Hospital Settings for People With Intellectual Disabilities: A Scoping Review Protocol. [PDF]

Campbell Syst Rev
Moloney M, Taggart L, Doody O.
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Acute hemorrhagic rectal ulcer in a child with severe motor and intellectual disabilities. [PDF]

Pediatr Int
Imagawa K, Deguchi T, Nemoto H, Morita A, Enokizono T, Takada H.   +5 more
europepmc   +1 more source

Pain Measurement in Infants and Children With and at Risk for Intellectual Disabilities. [PDF]

Paediatr Neonatal Pain
MacNeil M, Benoit B, Disher T, Newman AJ, Campbell-Yeo M.   +4 more
europepmc   +1 more source

Anthropometric and Body Composition Correlates of Hypertension in Children and Adolescents with Intellectual Disabilities. [PDF]

J Clin Med
Wyszyńska J, Dereń K, Mazur A, Matłosz P.   +3 more
europepmc   +1 more source

Reimagining Sexual Abuse Prevention for Adolescents with Intellectual Disabilities: A Scoping Review of Educational Gaps and Inclusive Future Directions. [PDF]

J Multidiscip Healthc
Yati D, Hermayanti Y, Solehati T, Fitri SYR.   +3 more
europepmc   +1 more source

Navigating healthcare for adults with intellectual disabilities in Singapore: a qualitative study of barriers and facilitators to healthcare system access and care-seeking. [PDF]

BMC Glob Public Health
Chan FJH, Bin Aman MA, Puah LJR, Teo JSH, Chen S, Ali SH, Chan AY, Hildon ZJ.   +7 more
europepmc   +1 more source